Novartis Drug Kisqali Improves Survival in Early Breast Cancer Patients

Novartis announced that its drug Kisqali, combined with endocrine therapy, significantly improved overall survival in high-risk early breast cancer patients. A six-year follow-up of the Phase III NATALEE trial showed a nearly 20% reduction in death risk for patients with stage II and III HR+/HER2- early breast cancer. This data reinforces the drug's benefit in preventing recurrence and extending lives.